Chapter 11

This is a listing of all citations in this chapter.

121

“Statement by the Dengue Vaccine Initiative on the Philippines Regulatory Approval of Sanofi Pasteur’s Dengue Vaccine, Dengvaxia®,” Sabine Institute, Press Release (Dec. 23, 2015).

122

Michaeleen Doucleff, “Rush To Produce, Sell Vaccine Put Kids in Philippines at Risk,” NPR (May 3, 2019).

123

Sri Rezeki Hadinegoro et al., “Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease,” New England Journal of Medicine (Sep. 24, 2015).

124

Scott B. Halstead, “Dengvaxia concern flagged nearly 2 years before Philippines pulls dengue vaccine,” Infectious Disease News (Dec. 5, 2017).

125

Scott B. Halstead, “Scott Halstead on Dengvaxia,” YouTube (Dec. 16, 2017).

126

Scott B. Halstead, “Critique of World Health Organization Recommendation of a Dengue Vaccine,” Journal of Infectious Diseases (Dec. 15, 2016).

127

Betsy McKay, et al., “Safety Fears Threaten Global Dengue Vaccine Effort,” Wall Street Journal (Jan. 8, 2019).

128

Michaeleen Doucleff, “Rush To Produce, Sell Vaccine Put Kids in Philippines at Risk,” NPR (May 3, 2019).

129

Michaeleen Doucleff, “Rush To Produce, Sell Vaccine Put Kids in Philippines at Risk,” NPR (May 3, 2019).

130

“Safety Fears Threaten Global Dengue Vaccine Effort, Wall Street Journal (Jan. 8, 2018).

131

“Merck and Instituto Butantan Announce Collaboration Agreement to Develop Vaccines to Protect Against Dengue Infections,” Business Wire (Dec. 12, 2018).

132

Michaeleen Doucleff, “Rush To Produce, Sell Vaccine Put Kids in Philippines at Risk,” NPR (May 3, 2019).

133

Eriko Padron-Regalado, et al., “Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains” Infect Dis Ther (April 23, 2020), doi: 10.1007/s40121-020-00300-x.

134

Chien-Te Tseng, et al., “Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus,” PLoS One (Apr.20, 2012), doi: 10.1371/journal.pone.0035421.

135

Damon Deming, et al., “Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants,” PLOS MED (Dec. 26, 2006), doi: 10.1371/journal.pmed.0030525.

136

Hana Weingartl, et al., “Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets,” J Virol (Nov. 2004), doi: 10.1128/JVI.78.22.12672-12676.2004.

137

Yiu Wing Kam, et al., “Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro,” Vaccine (Aug. 22, 2006), doi: 10.1016/j.vaccine.2006.08.011.

138

Anurodh Shankar Agrawal, et al., “Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus,” Hum Vaccin Immunother (June 7, 2016), doi: 10.1080/21645515.2016.1177688.

139

Anwar M. Hashem, et al. “A highly immunogenic, protective, and safe adenovirus-based vaccine expressing middle east respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model,” J Infect Dis. (July 4, 2019), doi: 10.1093/infdis/jiz137.

140

Children’s Health Defense, “The Dengue Vaccine: A Cautionary Tale,” CHD (Aug. 25, 2020).

141

Rachel L. Roper and Kristina E Rehm, “SARS vaccines: where are we?,” Expert Review of Vaccines 8 no. 7 (2009): 887–898, doi:10.1586/erv.09.43.

142

Conor Skelding, “Fauci email dump includes ‘sick’ March Madness-style virus bracket,” New York Post (Jun. 5, 2021).